Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors

Investigational New Drugs

Volumn 23, Issue 3, 2005, Pages 213-224

  Liang, Jian ^a   Moore, Richard E ^a   Moher, Eric D ^b   Munroe, John E ^b   Al Awar, Rima S ^b   Hay, David A ^b   Varie, David L ^b   Zhang, Tony Y ^b   Aikins, James A ^b   Martinelli, Michael J ^b   Shih, Chuan ^b   Ray, James E ^b   Gibson, Lowell L ^b   Vasudevan, Vasu ^b   Polin, Lisa ^c   White, Kathryn ^c   Kushner, Juiwanna ^c   Simpson, Chiab ^c   Pugh, Susan ^c   Corbett, Thomas H ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tumor; Cryptophycin; Glycinate; Mice; Preclinical

Indexed keywords

ALPHA CHLOROHYDRIN; CARMUSTINE; CISPLATIN; CRYPTOPHYCIN 1; CRYPTOPHYCIN 249; CRYPTOPHYCIN 283; CRYPTOPHYCIN 292; CRYPTOPHYCIN 296; CRYPTOPHYCIN 309; CRYPTOPHYCIN 52; CRYPTOPHYCIN 55; CRYPTOPHYCIN 8; CRYPTOPHYCIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ESTER; ETOPOSIDE; FLUOROURACIL; GLYCINE DERIVATIVE; LSN 355702; LSN 366703; LSN 368422; LSN 415320; LSN 418486; LSN 439049; LSN 440094; LSN 440264; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; CANCER STAGING; CANCER TRANSPLANTATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; EXAMINATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MATERIALS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CARCINOMA; PARALYTIC ILEUS; PRIORITY JOURNAL; SEPSIS; SKIN BRUISING; SKIN DISCOLORATION; THROMBOCYTOPENIA; TISSUE NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; EPOXY COMPOUNDS; ESTERS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 21044434617     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-6729-9     Document Type: Article

References (35)

1. Schwartz RE, Hirsch CF, Sesin DF, Flor JE, Chartrain M, Fromeling RE, Harris GH, Salvatore MJ, Liesch JM, Yudin K: Pharmaceuticals from cultured algae. J Ind Microbiol 5: 113-124, 1990
2. Golakoti T, Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchik L: Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga NOSTOC sp. Strain GSV 224. J Am Chem Soc 116: 4729-4737, 1994
3. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, and Moore R: Discovery of Cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15: 207-218, 1997
4. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH: Interaction of Cryptophycin 1 with Tubulin and Microtubules.FEBS Lett 377: 59-61, 1995
5. Panda D, Himes RH, Moore RE, Wilson L, Jordan MA: Mechanism of action of the unusually potent microtubule inhibitor Cryptophycin 1. Biochem 36: 12948-12953, 1997
6. Mooberry SL, Busquets L, Tien G: Induction of apoptosis by Cryptophycin 1, a new antimicrotubule agent. Int J Cancer 73: 440-448, 1997
7. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of Cryptophycin-8. J Exp Ther Oncol 1: 95-108, 1996
8. Barrow R, Hemscheidt T, Paik S, Liang J, Moore RE, Tius MA: Total synthesis of cryptophycins. Revision of the structures of Cryptophycins A and C. J Am Chem Soc 117: 2479-2490, 1995
9. Polin L, Valeriote F, Moore R, Tius M, Barrow R, Hemscheidt T, Liang J, Paik S, White K, Harrison S, Shih J, Martinelli M, Corbett T: Preclinical antitumor activity of Cryptophycin-52/55 (C-52, C-55) against human tumors in SCID mice [abstract]: Proc Am Assoc Cancer Res 38: 225, 1997
10. Corbett T, Valeriote F, Simpson C, Moore R, Tius M, Barrow R, Hemscheidt T, Liang J, Paik S, Polin L, Pugh S, Kushner J, Harrison S, Shih J, Martinelli M: Preclinical antitumor activity of Cryptophycin-52/55 (C-52, C-55) against mouse tumors [abstract]: Proc Am Assoc Cancer Res 38: 225, 1997
11. Worzalla JF, Cao J, Ehlhardt WJ, Harrison SD, Law KL, Martinelli MJ, Self TD, Starling JJ, Shih C, Theobald KS, Toth JE, Zimmermann JL, Corbett TH: LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts [abstract]: Proc Am Assoc Cancer Res 38: 225, 1997
12. Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ: Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res 8: 2524-2529, 2002
13. Sessa C, Weigang-Kohler K, Pagani O, Greim G, Mora O, DePas T, Burgess M, Weimer I, Johnson R: Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur J Cancer 38: 2388-2396, 2002
14. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery M-C, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Shaw JM, Liverside G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacognosy, Supp 33: 102-122, 1995
15. Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Shaw M, Golakoti T, Patterson G, Moore R, Corbett TH: Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15: 99-108, 1997
16. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lisow L: In vivo methods for screening and preclinical testing: Use of rodent solid tumors for drug discovery. In: B Teicher (ed) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press Inc, Totowa, New Jersey, 1997, Chapt. 5, pp. 75-99
17. Corbett TH, Polin L, Roberts BJ, Lawson AJ, Leopold III WR, White K, Kushner J, Paluch J, Hazeldine S, Moore R, Rake J, Horwitz J P: Transplantable syngeneic rodent tumors: Solid tumors of mice. In: B Teicher (ed) Tumor Models in Cancer Research. Humana Press Inc, Totowa, New Jersey, 2001, Chapt. 3, pp. 41-71
18. Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: RF Kallman (ed) Use of Rodent Tumors in Experimental Cancer Therapy. Pergamon Press, New York, 1987, Chapter 50, pp 233-247
19. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5: 3-20, 1987
20. Corbett TH, Bissery M-C, LoRusso P-M, Polin L: 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 7: 37-49, 1989
21. Corbett TH, Valeriote FA, Polin L, Panchapor C, Pugh S, White K, Lowichik N, Knight J, Bissery M-C, Wozniak A, LoRusso P, Biernat L, Polin D, Knight L, Biggar S, Looney D, Demchik L, Jones J, Jones L, Blair S, Palmer K, Essenmacher S, Lisow L, Mattes KC, Cavanaugh PF, Rake JB, Baker L: Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In: FA Valeriote, TH Corbett, LH Baker (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Kluwer Academic Publishers, Boston/Dordrecht, London, 1992, pp. 33-87
22. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42: 1707-1715, 1982
23. Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold Jr DP, Schabel Jr FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187-1200, 1982
24. Biernat L, Polin L, Corbett T: Adaptation of mammary tumors of mice to a soft agar assay for use in drug discovery. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract #185, Amsterdam, March 17-20, 1992
25. Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH: Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905-922, 1983. Corrected tables published in Cancer Treat Rep 68: 453-459, 1984.
26. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62(10): 1471-1488, 1978
27. Corbett TH, Griswold Jr DP, Roberts BJ, Schabel Jr, FM: Cytotoxic adjuvant therapy and the experimental model. In: BA Stoll (ed) New Aspects of Breast Cancer, Vol. 4, Systemic Therapy in Breast Cancer. William Heinemann Medical Books, Ltd, London, 1981, Chapt. 10, pp. 204-243
28. Corbett TH, Griswold Jr, DP, Roberts BJ, Peckham JC, Schabel Jr, FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660-2680, 1977
29. Corbett TH, Griswold Jr, DP, Roberts BJ, Peckham J, Schabel Jr, FM: A mouse colon tumor model for experimental therapy. Cancer Treat Rep Part 2, 5(1): 169-186, 1975
30. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr, FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984
31. Dexter DL, Barbosa JA, Calabresi P: N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39: 1020-1025, 1979
32. Alvarez M, Paull K, Monks A, Hose C, Lee J-S, Weinstein J, Grever M, Bates S, Fojo T: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 95: 2205-2214, 1995
33. Brattain MG, Fine WD, Khaled FM, Thomson J, Brattain DE: Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756, 1981
34. Boinpally RR, Polin L, Zhou S-L, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE: Pharmacokinetics and tissue distribution of Cryptophycin 52 (C-52) epoxide and Cryptophycin 55 (C-55) in mice with subcutaneous tumors. Clin Chemo Pharm 52: 25-33, 2003
35. Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K, Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P, Horwitz JP, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, Rake J: Preclinical efficacy of thioxanthone SR-271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs 17: 17-27, 1999